Recent 8-K filings for BIOA

• August 5, 2026, 4:55 PM ET earnings materiality 0.60 neutral item 2.02item 9.01

  BioAge Labs Q2 net loss $26.1M; dosed first participant in Phase 2 BGE-102 trial

  Net loss $26.1M ($0.58/share) vs $21.6M ($0.60/share) in Q2 2025; R&D spend up $4.6M to $24.4M.

• June 12, 2026, 8:00 AM ET other material materiality 0.15 neutral item 5.07 ◈ Shareholder Votes ×2

  BioAge Labs shareholders elect three Class II directors, ratify KPMG at annual meeting

  Class II directors elected: Patrick Enright (30.1M for, 1.2M withheld), James Healy (25.5M for, 5.8M withheld), Rekha Hemrajani (27.8M for, 3.4M withheld).

• May 8, 2026, 7:59 PM ET earnings materiality 0.75 neutral item 2.02item 9.01 ◈ Earnings Releases

  BioAge Labs Q1 net loss $22.3M; positive Phase 1 data for BGE-102 NLRP3 inhibitor

  Net loss $22.3M ($0.52 diluted EPS) vs $12.9M ($0.36) in Q1 2025; R&D spend rose to $20.4M.

• March 24, 2026, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 7.01item 9.01

  BioAge reports FY2025 net loss $80.6M; positive BGE-102 Phase 1 data; $132M offering

  Positive interim Phase 1 data for BGE-102: 86% median hsCRP reduction, 93% of obese participants reached <2 mg/L.

• January 22, 2026, 6:59 PM ET other material materiality 0.60 neutral item 1.01item 7.01item 9.01 ◈ Material Agreements

  BioAge Labs prices upsized $115M public offering of 5.9M shares at $19.50/share

  5,897,435 shares offered at $19.50/share; gross proceeds ~$115M, net ~$107.6M.

• January 20, 2026, 6:59 PM ET other material materiality 0.60 positive item 7.01item 8.01item 9.01

  BioAge Labs expands BGE-102 into diabetic macular edema; Phase 1b/2a trial planned mid-2026

  Plans to initiate Phase 1b/2a proof-of-concept trial in DME in mid-2026; results expected mid-2027.

• January 12, 2026, 6:59 PM ET other material materiality 0.75 positive item 7.01item 8.01item 9.01

  BioAge positive Phase 1 data for BGE-102: 86% hsCRP reduction, 93% normalized

  BGE-102 achieved 86% median hsCRP reduction at Day 14 in obese patients with elevated baseline hsCRP; 93% reached <2 mg/L.

• December 4, 2025, 6:59 PM ET other material materiality 0.75 positive item 7.01item 8.01item 9.01

  BioAge reports positive Phase 1 interim data for NLRP3 inhibitor BGE-102; 90-98% IL-1β suppression

  BGE-102 well-tolerated across all doses (SAD: 10-120 mg; MAD: 60-120 mg); AEs mild/moderate, all resolved.

• November 6, 2025, 6:59 PM ET earnings materiality 0.60 neutral item 2.02item 9.01

  BioAge Q3 net loss $20.2M; first participant dosed in BGE-102 Phase 1 trial

  Net loss of $20.2M ($0.56 EPS) vs $23.4M ($6.70) in Q3 2024; collaboration revenue $2.1M from Novartis deal.

• August 6, 2025, 7:59 PM ET earnings materiality 0.55 neutral item 2.02item 9.01

  BioAge Labs Q2 net loss $21.6M, cash $313.4M; BGE-102 Phase 1 on track for 2H 2025

  Net loss $21.6M ($0.60/share) vs $13.6M loss in Q2 2024; R&D expenses rose to $19.8M.

• June 9, 2025, 7:59 PM ET other materiality 0.15 neutral item 5.07

  BioAge Labs shareholders elect three Class I directors; ratify KPMG as auditor

  Elected Class I directors Kristen Fortney, Eric Morgen, Vijay Pande to three-year terms expiring at 2028 annual meeting.

• June 4, 2025, 7:59 PM ET other material materiality 0.40 neutral item 8.01

  BioAge provides NLRP3 & APJ program timeline updates in corporate presentation

  NLRP3 program: IND submission and Phase 1 SAD/MAD initiation planned for mid-2025; initial SAD data expected by end of 2025.

• May 6, 2025, 7:59 PM ET earnings materiality 0.55 neutral item 2.02item 9.01

  BioAge Labs Q1 net loss $12.9M; cash $335.1M; BGE-102 Phase 1 data expected 2H25

  Net loss of $12.9M ($0.36 diluted EPS) vs $13.0M loss in Q1 2024; no revenue reported.

• March 20, 2025, 7:59 PM ET earnings materiality 0.70 neutral item 2.02item 9.01

  BioAge Labs FY2024 net loss $71.1M; advances NLRP3 inhibitor BGE-102; discontinues azelaprag

  Net loss of $71.1M ($6.63/share) for FY2024; cash $354.3M expected to fund operations through 2029.

• November 7, 2024, 6:59 PM ET earnings materiality 0.85 positive item 2.02item 9.01

  BioAge Labs Q3 net loss $23.4M; IPO proceeds extend cash runway into 2029

  Net loss of $23.4M ($6.70/share) vs $14.6M ($8.74/share) in Q3 2023; R&D spend rose to $20.0M on Phase 2 STRIDES trial.

• September 27, 2024, 7:59 PM ET other material materiality 0.35 neutral item 1.01item 3.02item 9.01

  BioAge Labs sells 588,888 shares to Sofinnova at $18 in private placement concurrent with IPO

  Private placement of 588,888 shares to existing stockholder Sofinnova at IPO price of $18.00/share, raising $10.6 million.

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.85 · Median 0.60 · Most common event earnings

5 positive 0 negative 11 neutral

source · BIOA on sec.gov